Business ❯ Finance ❯ Investments ❯ Stocks

Pharmaceutical Stocks

Analysts Reinforce Eli Lilly’s Bull Case on Strong 2026 Guide, GLP-1 Momentum

Fresh targets follow a robust outlook that has sharpened investor focus on execution.

ImmunityBio Rallies as Anktiva Sales Surge 700% and Registrational Trial Passes 85% Enrollment

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

Crinetics Wins FDA Approval for Oral Acromegaly Drug Palsonify as JMP Lifts Price Target